BioScrip Inc (BIOS) Given Average Recommendation of “Buy” by Analysts

BioScrip Inc (NASDAQ:BIOS) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $3.83.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 target price on shares of BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th.

Shares of BioScrip (BIOS) opened at $3.11 on Tuesday. The stock has a market cap of $396.57, a P/E ratio of -5.02 and a beta of 0.27. BioScrip has a fifty-two week low of $1.21 and a fifty-two week high of $3.39. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. The company’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. analysts predict that BioScrip will post -0.63 earnings per share for the current fiscal year.

In other BioScrip news, CEO Daniel E. Greenleaf purchased 15,000 shares of the company’s stock in a transaction on Thursday, November 9th. The stock was acquired at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the purchase, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at approximately $62,930. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in BioScrip in the 3rd quarter worth approximately $114,000. Voya Investment Management LLC boosted its stake in BioScrip by 41.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after purchasing an additional 14,867 shares during the period. Highbridge Capital Management LLC bought a new position in BioScrip in the 3rd quarter worth approximately $153,000. The Manufacturers Life Insurance Company boosted its stake in BioScrip by 9.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock worth $271,000 after purchasing an additional 8,914 shares during the period. Finally, Skylands Capital LLC bought a new position in BioScrip in the 3rd quarter worth approximately $272,000. Institutional investors and hedge funds own 84.53% of the company’s stock.

WARNING: “BioScrip Inc (BIOS) Given Average Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/bioscrip-inc-bios-given-average-recommendation-of-buy-by-analysts.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply